Anaphylaxis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Anaphylaxis - Pipeline Review, H1 2016', provides an overview of the Anaphylaxis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Anaphylaxis - The report reviews pipeline therapeutics for Anaphylaxis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Anaphylaxis therapeutics and enlists all their major and minor projects - The report assesses Anaphylaxis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Anaphylaxis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Anaphylaxis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Anaphylaxis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Anaphylaxis Overview 7 Therapeutics Development 8 Pipeline Products for Anaphylaxis - Overview 8 Pipeline Products for Anaphylaxis - Comparative Analysis 9 Anaphylaxis - Therapeutics under Development by Companies 10 Anaphylaxis - Therapeutics under Investigation by Universities/Institutes 11 Anaphylaxis - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Anaphylaxis - Products under Development by Companies 14 Anaphylaxis - Products under Investigation by Universities/Institutes 15 Anaphylaxis - Companies Involved in Therapeutics Development 16 Adamis Pharmaceuticals Corporation 16 Monosol Rx, LLC 17 Anaphylaxis - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 epinephrine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 epinephrine - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 epinephrine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Anaphylaxis - Recent Pipeline Updates 33 Anaphylaxis - Dormant Projects 34 Anaphylaxis - Product Development Milestones 35 Featured News & Press Releases 35 Dec 07, 2015: Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA 35 Aug 06, 2015: Adamis Pharmaceuticals Provides Regulatory Update on Its Epinephrine Pre-Filled Syringe 35 Mar 27, 2015: Adamis Pharmaceuticals Receives Complete Response Letter From FDA for Its Epinephrine Pre-Filled Syringe NDA 35 Oct 15, 2014: Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams 36 Jul 29, 2014: FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe 36 May 29, 2014: Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe 37 Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 38 Disclaimer 39
List of Tables
Number of Products under Development for Anaphylaxis, H1 2016 8 Number of Products under Development for Anaphylaxis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Anaphylaxis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 16 Anaphylaxis - Pipeline by Monosol Rx, LLC, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Anaphylaxis Therapeutics - Recent Pipeline Updates, H1 2016 33 Anaphylaxis - Dormant Projects, H1 2016 34
List of Figures
Number of Products under Development for Anaphylaxis, H1 2016 8 Number of Products under Development for Anaphylaxis - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certainRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.